|
 |
HelixateThis page contains recent news articles, when available, and an overview of Helixate but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The HeliTrax System, used in conjunction with Helixate FS treatment, is designed to improve patient-physician communications and therapy management. Earthtimes (press release), Annual Report to shareholders - Sep 11, 2008 Helixate. The productivity of our research and development team recombinant Factor VIII sales have continued to grow year was most rewarding with the Sydney Morning Herald, CSL Behring Provides $1.2M Grant for World's First Study of ... - Aug 18, 2008 Pasteurized, for the treatment of von Willebrand Disease, and Helixate® FS a recombinant factor VIII treatment for hemophilia A. Other products are used PR Newswire (press release), Cadient Group President and CEO Stephen Wray praises the region as - Jul 29, 2008 To create awareness of the firm's Helixate product, Cadient created www.hemophiliamoms.com, a site created for the mothers of children with blood disorders. Bizjournals.com, National Hemophilia Foundation Applauds First von Willebrand ... - May 6, 2008 ...a desmopression acetate for the treatment of mild hemophilia A or mild to moderate type 1 von Willebrand disease, and Helixate(R) FS a recombinant PR Newswire (press release), CSL Behring Signs Agreements With Canadian Blood Services and Hema ... - Apr 3, 2008 Helixate(R) FS should be administered cautiously in patients with previous hypersensitivity to constituents of FVIII preparations or known sensitivity to FOXBusiness CSL Behring wins contract to supply plasma-derived products - Apr 4, 2008 By Staff Writer The contracts call for CSL Behring to supply Helixate FS, Humate, Privigen, Vivaglobin and other life-saving therapies over a period of at Pharmaceutical Business Review Bayer Falls on Novartis Suit Over Kogenate Patent (Update1) - Feb 20, 2008 CSL Ltd.'s CSL Behring, which sells the medicine Helixate under an agreement with Bayer, also was sued. Novartis Vaccines and Diagnostics, the unit that Bloomberg Novartis sues Bayer over haemotology patent - Feb 20, 2008 AX unit CSL Behring for its Helixate medicine -- according to court documents filed by Novartis and Novo in a District court in Texas on Feb. 15. Reuters Neenah boy's diagnosis gives family a rare insight into bleeding ... - Mar 4, 2008 It is Sebastian's medicine, Helixate FS Antihemophilic Factor (Recombinant). He receives injections every other day in the permanent port installed in his Appleton Post Crescent, CSL Half Yearly Report and Half Year Accounts - Feb 19, 2008 Following a supplier agreement in the prior period to extend the supply of Helixate., patient numbers have increased steadily, particularly in the USA. Sydney Morning Herald, Recent patent/copyright infringement cases filed in US District Courts - Feb 21, 2008 Patent by making or using recombinant antihemophilic Factor VIII known under the trade names Kogenate and Helixate for use in patients with hemophilia. Southeast Texas Record, Europe agency warns on switching hemophilia drugs - Jul 31, 2007 MarketWatchDrugs authorized in Europe are Advate, Kogenate, Bayer/Helixate NexGen, Kogenate/Helixate and ReFacto, which are products of Baxter (BAX : EMEA Completes the Review of Recombinant Factor VIII Products and ... - Jul 31, 2007 PharmaLive.com (press release),Bayer/Helixate NexGen, Kogenate/Helixate and ReFacto. Recombinate is authorised through the mutual recognition procedure with the Netherlands acting as the : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |